Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the ''European organization for research and treatment of cancer'' (EORTC) protocol 30892

Author: Schroder F.   Whelan P.   De Reijke T.   Kurth K.   Pavone M.   Mattelaer J.   Van Velthoven R.   Dubois M.   Collete L.  

Publisher: Elsevier

ISSN: 1569-9056

Source: European Urology Supplements, Vol.2, Iss.1, 2003-02, pp. : 188-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content